E2F Inhibitor, HLM006474-CAS 353519-63-8-Calbiochem

C₂₅H₂₅N₃O₂

399.48

MFCD02168344

A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC₅₀ = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).
A cell-permeable 8-hydroxyquinoline compound that is reported to inhibit nuclear E2F complexes DNA binding activity (IC₅₀ = 30 µM) and downregulate E2F expression in the melanoma cell line A375, resulting in eventual apoptosis induction without upregulating p53 expression as commonly seen with traditional chemotherapeutic agents, such as Cisplatin (Cat. No. 232120), doxorubicin (Cat. No. 324380), and VP-16 (Cat. No. 341205).

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Ma, Y., et al. 2008. Cancer Res.68, 6292.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

100

≥95% (HPLC)

solid

Calbiochem^®

OK to freeze
protect from light

off-white

DMSO: 50 mg/mL

ambient

−20℃

10 mg in Glass bottle
Packaged under inert gas

11 - Combustible Solids

WGK 3